Company Performance Metrics
John-Michel T. Huss: President & CEO- Luc Tanguay: Senior Executive Vice President and CFO
Theratechnologies Inc., a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that increases the target protein's resistance to enzymatic degradation. Its lead product is tesamorelin, which
completed its phase III clinical trial for the treatment of HIV-associated lipodystrophy and is in phase II clinical trials for the treatment of mild cognitive impairment and growth hormone deficient abdominal obesity. The company also develops Acute kidney injury, a preclinical stage product. It has a license agreement with PDC Biotech GmbH to use the antagonists of the prostaglandin F2a receptor in pre-term labor and primary dysmenorrheal; and OctoPlus N.V. to develop and commercialize GLP-1 portfolio of analogues. The company also has a collaboration and licensing agreement with EMD Serono, Inc. for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded in 1993 and is headquartered in Montreal, Canada.
